Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc

Cancer Cell International

Volumn 10, Issue , 2010, Pages

  Luo, Haitao ^a   Daddysman, Matthew K ^a   Rankin, Gary O ^c   Jiang, Bing Hua ^b   Chen, Yi C ^a  

^a Alderson Broaddus College   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C1; ABC TRANSPORTER C5; ABC TRANSPORTER C6; ALPHA TOCOPHEROL DERIVATIVE; ALPHA TOCOPHEROL SUCCINATE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; FLAVONOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN 1; KAEMPFEROL; MESSENGER RNA; MYC PROTEIN; RUTOSIDE; TAXIFOLIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; GENE CONTROL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OVARY CANCER; PROTEIN EXPRESSION; UPREGULATION;

EID: 77951944654     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-10-16     Document Type: Article

References (20)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer Statistics, 2004. CA Cancer J Clin 2004, 54:8-29. 10.3322/canjclin.54.1.8, 14974761.
2. Perez RP, Godwin AK, Hamilton TC, Ozols RF. Ovarian cancer biology. Semin Oncol 1991, 18:186-204.
3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6. 10.1056/NEJM199601043340101, 7494563.
4. Bosetti C, Rossi M, McLaughlin JK, Negri E, Talamini R, Lagiou P, Montella M, Ramazzotti V, Franceschi S, LaVecchia C. Flavonoids and the risk of renal cell carcinoma. Cancer Epidemiol Biomarkers Prev 16:98-101. 10.1158/1055-9965.EPI-06-0769, 17220336.
5. Gonzalez CA, Riboli E. Diet and cancer prevention: where we are, where we are going. Nutr Cancer 2006, 56:225-31. 10.1207/s15327914nc5602_14, 17474869.
6. Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA, Jacobs DR. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr 2007, 85:895-909.
7. Bosetti C, Bravi F, Talamini R, Parpinel M, Gnagnarella P, Negri E, Montella M, Lagiou P, Franceschi S, La Vecchia C. Flavonoids and prostate cancer risk: a study in Italy. Nutr Cancer 2006, 56:123-7. 10.1207/s15327914nc5602_1, 17474856.
8. Theodoratou E, Kyle J, Cetnarskyj R, Farrington SM, Tenesa A, Barnetson R, Porteous M, Dunlop M, Campbell H. Dietary flavonoids and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:684-93. 10.1158/1055-9965.EPI-06-0785, 17416758.
9. Adhami VM, Malik A, Zaman N, Sarfaraz S, Siddiqui IA, Syed DN, Afaq F, Pasha FS, Saleem M, Mukhtar H. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2007, 13:1611-9. 10.1158/1078-0432.CCR-06-2269, 17332308.
10. Plochmann K, Korte G, Koutsilieri E, Richling E, Riederer P, Rethwilm A, Schreier P, Scheller C. Structure-activity relationships of flavonoid-induced cytotoxicity on human leukemia cells. Arch Biochem Biophys 2007, 460:1-9. 10.1016/j.abb.2007.02.003, 17353006.
11. Brabec V. Chemistry and structural biology of 1,2-intrastrand adducts of cisplatin. Platinum Based Drugs in Cancer Therapy 2000, 37-61. Totowa, NJ: Humana Press Inc, Kelladn LR, Farell NP, 1.
12. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, Li Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008, 15:1987-2039.
13. Shukla S, Gupta S. Suppression of Constitutive and Tumor Necrosis Factor α-Induced Nuclear Factor (NF)-κB Activation and Induction of Apoptosis by Apigenin in Human Prostate Carcinoma PC-3 Cells: Correlation with Down-Regulation of NF-κB-Responsive Genes. Clinical Cancer Research 2004, 10:3169-78. 10.1158/1078-0432.CCR-03-0586, 15131058.
14. Isonishi S, Ohkawa K, Tanaka T, Howell SB. Depletion of protein kinase C (PKC) by 12-O-tetradecanolyphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells. British J of Cancer 2000, 82:34-38.
15. Shi R, Huang Q, Zhu X, Ong YB, Zhao B, Lu J, Ong CN, Shen HM. Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization. Mol Cancer Ther 2007, 6:1338-47. 10.1158/1535-7163.MCT-06-0638, 17431112.
16. Banerjee S, Zhang Y, Wang Z, Che M, Chiao PJ, Abbruzzese JL, Sarkar FH. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer 2007, 120:906-17. 10.1002/ijc.22332, 17131310.
17. Luo H, Jiang B, King SM, Chen YC. Inhibition of Cell Growth and VEGF Expression in Ovarian Cancer Cells by Flavonoids. Nutrition and Cancer 2008, 60(6):800-809. 10.1080/01635580802100851, 19005980.
18. Sharma H, Sen S, Singh N. Molecular pathways in the chemosensitization of cisplatin by quercentin in human head and neck cancer. Cancer Biol Ther 2005, 4:949-55.
19. Jung P, Menssen A, Mayr D, Hermeking H. AP4 encodes a c-MYC-inducible repressor of p21. Proc Natl Acad Sci USA 2008, 105(39):15046-51. 10.1073/pnas.0801773105, 2553359, 18818310.
20. Seoane J, Le HV, Massagué J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002, 419(6908):729-34. 10.1038/nature01119, 12384701.